Cytokinetics Unveils New Data on Aficamten and Metoprolol in Hypertrophic Cardiomyopathy Trial
Reuters
Oct 31
<a href="https://laohu8.com/S/CYTK">Cytokinetics</a> Unveils New Data on Aficamten and Metoprolol in Hypertrophic Cardiomyopathy Trial
Cytokinetics Incorporated has announced several upcoming presentations featuring new clinical research at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions 2025, taking place November 7-10, 2025, in New Orleans, LA. Among the scheduled presentations are Late Breaking Science sessions on the effects of aficamten versus metoprolol on patient-reported health status in obstructive hypertrophic cardiomyopathy, with results to be presented on November 7 and November 8, 2025. Additional studies from the GALACTIC-HF trial focusing on lactate dehydrogenase, urine dipstick protein assessments, and their association with clinical outcomes in heart failure patients with reduced ejection fraction will also be presented. The results from these studies are scheduled to be shared at the upcoming conferences and have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565938-en) on October 31, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.